Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F James

Showing results (981-990 of 1,011) with videos related to

Pageof 102
Sort By:
Nature|May 21, 2020
TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9Leonhard X Heinz, JangEun Lee, Utkarsh Kapoor, et al.
The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
The Review of Scientific Instruments|July 2, 2018
Characterisation of a sub-20 ps temporal resolution pulse dilation photomultiplier tubeS G Gales, C J Horsfield, A L Meadowcroft, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Journal of Neurointerventional Surgery|September 18, 2017
Evaluation of previously embolized intracranial aneurysms: inter-and intra-rater reliability among neurosurgeons and interventional neuroradiologistsScott L Zuckerman, Nikita Lakomkin, Jordan A Magarik, et al.
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.
Physical Review. E|May 14, 2016
Plasma scale-length effects on electron energy spectra in high-irradiance laser plasmasO Culfa, G J Tallents, A K Rossall, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Pageof 102

Showing results (981-990 of 1,011) with videos related to

Sort By:
Pageof 102
Nature|May 21, 2020
TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9Leonhard X Heinz, JangEun Lee, Utkarsh Kapoor, et al.
The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
The Review of Scientific Instruments|July 2, 2018
Characterisation of a sub-20 ps temporal resolution pulse dilation photomultiplier tubeS G Gales, C J Horsfield, A L Meadowcroft, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Journal of Neurointerventional Surgery|September 18, 2017
Evaluation of previously embolized intracranial aneurysms: inter-and intra-rater reliability among neurosurgeons and interventional neuroradiologistsScott L Zuckerman, Nikita Lakomkin, Jordan A Magarik, et al.
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.
Physical Review. E|May 14, 2016
Plasma scale-length effects on electron energy spectra in high-irradiance laser plasmasO Culfa, G J Tallents, A K Rossall, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Pageof 102